HDIM
VRTX icon

Hanson & Doremus Investment Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Hanson & Doremus Investment Management’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$265K Sell
534
-20
-4% -$8.86K 0.03% 177
2026
Q1 		$247K Hold
554
– – 0.03% 174
2025
Q4 		$251K Buy
554
+20
+4% +$8.62K 0.03% 175
2025
Q3 		$209K Sell
534
-36
-6% -$15K 0.03% 200
2025
Q2 		$254K Buy
570
+200
+54% +$92.2K 0.03% 176
2025
Q1 		$179K Buy
370
+300
+429% +$140K 0.03% 197
2024
Q4 		$28K Hold
70
– – ﹤0.01% 346
2024
Q3 		$33K Hold
70
– – 0.01% 331
2024
Q2 		$33K Hold
70
– – 0.01% 330
2024
Q1 		$29K Hold
70
– – 0.01% 343
2023
Q4 		$28K Sell
70
-5
-7% -$1.85K 0.01% 340
2023
Q3 		$26K Hold
75
– – 0.01% 337
2023
Q2 		$26K Hold
75
– – 0.01% 343
2023
Q1 		$24K Hold
75
– – 0.01% 360
2022
Q4 		$22K Hold
75
– – ﹤0.01% 393
2022
Q3 		$22K Buy
+75
New +$21.6K 0.01% 374
2021
Q2 		– Sell
-7
Closed -$2K – 531
2021
Q1 		$2K Buy
+7
New +$1.54K ﹤0.01% 491

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Hanson & Doremus Investment Management's VRTX Position: Q2 2026 in Review

Hanson & Doremus Investment Management reduced its Vertex Pharmaceuticals (VRTX) stake by 3.6% in Q2 2026, selling an estimated $8.86K and leaving 534 shares worth $265K. The position accounts for 0.03% of the portfolio, ranked #177.

Hanson & Doremus Investment Management first reported a position in VRTX in Q1 2021 and has held it in 17 quarters since. 1,747 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Hanson & Doremus Investment Management held 534 shares of Vertex Pharmaceuticals worth $265K as of Q2 2026.
  • Hanson & Doremus Investment Management sold 20 Vertex Pharmaceuticals shares in Q2 2026, an estimated $8.86K.
  • Vertex Pharmaceuticals made up 0.03% of Hanson & Doremus Investment Management's portfolio in Q2 2026, its #177 holding.
  • Hanson & Doremus Investment Management first reported a position in Vertex Pharmaceuticals in Q1 2021 and has held it in 17 quarters since.
  • 1,747 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Hanson & Doremus Investment Management's 13F filing for Q2 2026, filed 29 Jul 2026.